Wells Fargo
ADVM

Wells Fargo’s Adverum Biotechnologies ADVM Stock Holding History

Wells Fargo’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30
Closed -$136 – 7100
2025
Q3 		$136 Sell
30
-184
-86% -$542 ﹤0.01% 6363
2025
Q2 		$461 Sell
214
-12,317
-98% -$34.5K ﹤0.01% 6380
2025
Q1 		$54.8K Buy
12,531
+291
+2% +$1.31K ﹤0.01% 5367
2024
Q4 		$57.2K Buy
12,240
+2,659
+28% +$17.9K ﹤0.01% 5438
2024
Q3 		$67.3K Buy
9,581
+441
+5% +$3.2K ﹤0.01% 5232
2024
Q2 		$62.7K Buy
9,140
+8,998
+6,337% +$83.7K ﹤0.01% 5205
2024
Q1 		$2.01K Buy
142
+44
+45% +$669 ﹤0.01% 6034
2023
Q4 		$735 Sell
98
-96
-49% -$876 ﹤0.01% 6303
2023
Q3 		$2.91K Buy
194
+127
+190% +$2.28K ﹤0.01% 6045
2023
Q2 		$1.07K Buy
67
+3
+5% +$32 ﹤0.01% 6309
2023
Q1 		$460 Buy
64
+1
+2% +$7 ﹤0.01% 6573
2022
Q4 		$366 Buy
63
+2
+3% +$15 ﹤0.01% 6472
2022
Q3 		$1K Sell
61
-14
-19% -$184 ﹤0.01% 6254
2022
Q2 		$1K Sell
75
-824
-92% -$8.63K ﹤0.01% 6449
2022
Q1 		$11K Sell
899
-3,037
-77% -$44.4K ﹤0.01% 6226
2021
Q4 		$69K Buy
3,936
+3,930
+65,500% +$78.7K ﹤0.01% 5812
2021
Q3 		$0 Sell
6
-25
-81% -$638 ﹤0.01% 6915
2021
Q2 		$1K Sell
31
-1,242
-98% -$66.9K ﹤0.01% 6607
2021
Q1 		$126K Sell
1,273
-6,542
-84% -$786K ﹤0.01% 5380
2020
Q4 		$848K Buy
7,815
+3,293
+73% +$407K ﹤0.01% 4152
2020
Q3 		$467K Sell
4,522
-364
-7% -$54.5K ﹤0.01% 4397
2020
Q2 		$1.02M Buy
4,886
+1,381
+39% +$245K ﹤0.01% 3804
2020
Q1 		$343K Sell
3,505
-17,950
-84% -$2.09M ﹤0.01% 4318
2019
Q4 		$2.47M Buy
21,455
+18,703
+680% +$1.65M ﹤0.01% 3183
2019
Q3 		$150K Buy
2,752
+48
+2% +$5.41K ﹤0.01% 5127
2019
Q2 		$322K Sell
2,704
-293
-10% -$24.2K ﹤0.01% 4682
2019
Q1 		$157K Buy
2,997
+102
+4% +$4.12K ﹤0.01% 4937
2018
Q4 		$91K Sell
2,895
-519
-15% -$21.1K ﹤0.01% 5327
2018
Q3 		$206K Buy
3,414
+2,147
+169% +$121K ﹤0.01% 4984
2018
Q2 		$67K Buy
1,267
+667
+111% +$40.1K ﹤0.01% 5515
2018
Q1 		$35K Buy
+600
New +$37.4K ﹤0.01% 5665
2017
Q3 		– Sell
-20
Closed -$1K – 6290
2017
Q2 		$1K Sell
20
-1,425
-99% -$39K ﹤0.01% 6087
2017
Q1 		$39K Sell
1,445
-4,170
-74% -$119K ﹤0.01% 5530
2016
Q4 		$163K Buy
5,615
+4,170
+289% +$136K ﹤0.01% 4872
2016
Q3 		$59K Hold
1,445
– – ﹤0.01% 5217
2016
Q2 		$46K Buy
1,445
+1,051
+267% +$47.5K ﹤0.01% 5228
2016
Q1 		$20K Buy
394
+78
+25% +$4.36K ﹤0.01% 5517
2015
Q4 		$30K Sell
316
-62
-16% -$5.45K ﹤0.01% 5458
2015
Q3 		$31K Buy
378
+18
+5% +$2.3K ﹤0.01% 5409
2015
Q2 		$58K Sell
360
-449
-56% -$151K ﹤0.01% 5282
2015
Q1 		$329K Buy
809
+777
+2,428% +$328K ﹤0.01% 4180
2014
Q4 		$17K Buy
+32
New +$12.3K ﹤0.01% 5429

Wells Fargo's ADVM Position: Q4 2025 in Review

Wells Fargo sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 30 shares — an estimated $136 sold.

Wells Fargo first reported a position in ADVM in Q4 2014 and held it in 42 quarters. The position peaked at $2.47M in Q4 2019. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • Wells Fargo reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Wells Fargo sold 30 Adverum Biotechnologies shares in Q4 2025, an estimated $136.
  • Wells Fargo first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 42 quarters.
  • Wells Fargo's Adverum Biotechnologies position peaked at $2.47M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on Wells Fargo's 13F filing for Q4 2025, filed 13 Feb 2026.